1. TAZMEEN FADRA-KHAN DRUG DISCOVERYPROFESSIONAL
203.240.6575  tnfadra@gmail.com 15 Boughton Street #11  Danbury, CT 06810
Versatile and innovative professional with extensive data analysis experience within multiple technical environments.
Analytical strategist skilled in successfully implementing processes that enhance organizational initiatives and deliver
improved data utilization. Collaborative communicator focused on building relationships and promoting synergy across
research programs. Proven record of leading complex projects from inception to completion. Areas of Expertise include:
 Strategic Planning & Analysis  Data Management & Reporting  Project Management
 Lean Six Sigma Methodologies  Screening Technologies  Laboratory Operations
 Medical Technology & Equipment  Staff Training & Leadership  In vitro Assays
EXPERIENCE & NOTABLE CONTRIBUTIONS
BOEHRINGER INGELHEIM PHARMACEUTICALS INC.  Ridgefield, CT  2002 to Present
SCIENTIST I,II, III
Independently handle comprehensive screening of NMEs by utilizing SAR-driving, cell-based, biochemical and
radioactive assays. Proficient in contributing to hit qualification and hit-to-lead progression. Guide cell bank creation
and maintenance, execute transfections and develop cell cultures. Skilled in hERG QPatch assay for cardiotox profiling.
KEY ACCOMPLISHMENTS:
 Implement molecular, cellular, enzymatic and biochemical assays to expedite new lead identification and drug
discoveries.
 Improve data quality and throughput by building assays that support SAR and through the evaluation,
troubleshooting and automation of a wide-range of assay technologies.
 Leverage AlphaScreen, HTRF, Electrochemiluminescence (ECL), ELISA, SPA and fluorescence and luminescence
detection methods associated with high-throughput assays in 96-well and 384-well assay formats.
 Establish protocols on automated liquid handlers and plate readers including ECHO Acoustic Dispenser, CyBi Well
Vario, Beckman Coulter Biomek FX, Perkin Elmer ViewLux & Envision, Molecular Devices LJL-analyst, Cedex and
Countess cell counters, and the MSD Sector Imagers.
 Prepare and generate data analysis reports with Excel Fit, Activity Base, MegaLab and SARgen, and author internal
documents that support IND submissions.
 Administer electronic laboratory record keeping, laboratory equipment maintenance and overall quality controls.
 Push a team of six associate scientists to establish Best Practices Guidelines to ensure consistency in methodologies
across projects, and provide training to new employees to ensure adherence to laboratory standards.
YOH SCIENTIFIC  Ridgefield, CT  2002
RESEARCH ASSISTANT
Directed the execution of immunoassays associated with secondary screening for a high-throughput screening
laboratory. Supported a proper mammalian cell culture and cell banks by prioritizing sterile techniques. Cultivated
capabilitiesin properly managing and disposing human-based bio-hazardous materials. Ensured accurate records of all
assay activities.
KEY ACCOMPLISHMENTS:
 Optimized ECL, DELFIA and ELISA methods to perform secondary screening assays.
 Increased automation functions with instruments including IGEN M-Series Analyzer, LJL-Analyst, and Sagian
Multimek.
 Facilitated lead-optimization and hit-to-lead studies with cell-based assay activities.
 Steered computational and visualization functions and reporting with Excel and ActivityBase capabilities.
Additional Experience Includes:
STATE UNIVERSITY OF NEW YORK AT BUFFALO, EDUCATIONAL OPPORTUNITY TUTOR, NEW YORK 2000 – 2002
REGENERSON PHARMACEUTICALS INC, INTERN, NEW YORK 2001
PD HINDUJA NATIONAL HOSPITAL, MEDICAL TECHNOLOGIST, INDIA 1999 – 2000

2. TAZMEEN FADRA-KHAN PAGE TWO
PD HINDUJA NATIONAL HOSPITAL, MEDICAL TECHNOLOGIST INTERN, INDIA 1999
TECHNICAL PROFICIENCIES
ActivityBase ExcelFit SARgen/SARview SpotFire MegaLab Microsoft Office
EDUCATION & TRAINING
Master of Arts in Microbiology | STATE UNIVERSITY OF NEW YORK AT BUFFALO | Buffalo, NY
Bachelor of Science in Microbiology | UNIVERSITY OF MUMBAI | India
Diploma with First Class and Distinction in Clinical Analysis | SOPHIA COLLEGE | India
Candidate for Lean Six Sigma Certification
PUBLICATIONS
 Harcken, C., Riether, D., Liu, P., Razavi, H., Patel, U., Lee, T., Fadra-Khan, T., et al. (2014). Optimization of Drug-like
Properties of Non-steroidal Azaindole Glucocorticoid Mimetics and Identification of a Clinical Candidate. ACS
Medicinal Chemistry Letters
 Razavi, H., Riether, D., Harcken, C., Bentzien, J., Dinallo, R., Souza, D., Fadra-Khan, T., et al. (2014). Discovery of a
potent and dissociated non-steroidal glucocorticoid receptor agonist containing an alkyl
carbinolpharmacophore. Bioorganic & Medicinal Chemistry Letters, 24(8), 1934-1940
 Harcken, C., Riether, D., Kuzmich, D., Liu, P., Betageri, R., Ralph, M., Fadra, T., et al. (2014). Identification of highly
efficacious glucocorticoid receptor agonists with a potential for reduced clinical bone side effects. Journal of
Medicinal Chemistry, 57(4), 1583-1598
 Kuzmich, D., Bentzien, J., Betageri, R., DiSalvo, D., Fadra-Khan, T., et al. (2013). Function-regulating
pharmacophores in a sulfonamide classof glucocorticoid receptor agonists. Bioorganic & Medicinal Chemistry
Letters,23(24), 6640-6644
 DiSalvo, D., Kuzmich, D., Bentzien, J., Regan, J., Kukulka, A., Fadra-Khan, T., et al (2013), Substituted phenyl as a
steroid A-ring mimetic: Providing agonistactivity to a class of arylsulfonamidenonsteroidal
glucocorticoidligands. . Bioorganic & Medicinal Chemistry Letters,23(24), 6645-6649
 Betageri, R., Gimore, T., Kuzmich, D., Kirrane, T., Bentzien, J., Wiedenmayer, D., Fadra, T., et al. (2011). Non-
steroidal dissociated glucocorticoid agonists: indoles as A-ringmimetics and function-regulating
pharmacophores. Bioorganic & Medicinal Chemistry Letters, 21(22), 6842-6851
 Riether, D., Harcken, C., Razavi, H., Kuzmich, D., Gilmore, T., Bentzien, J., Fadra, T., et al. (2010). Nonsteroidal
dissociated glucocorticoid agonists containing azaindoles as steroid A-ring mimetics. Journal of Medicinal
Chemistry, 53(18), 6681-6698
 Cirillo, P. F., Hickey, E. R., Moss, N., Breitfelder, S., Betageri, R., Fadra, T., et al. (2009). Discovery and
characterization of the N-phenyl-N′-naphthylurea class of p38 kinase inhibitors. Bioorganic and Medicinal
Chemistry Letters, 19(9), 2386-2391
 Cogan, D. A., Aungst, R., Breinlinger, E. C., Fadra, T., Goldberg, D. R., Hao, M. H., et al. (2008). Structure-based
design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Bioorganic and Medicinal Chemistry Letters, 18(11), 3251-3255
 Goldberg, D. R., Hao, M., Qian, K. C., Swinamer, A. D., Gao, D. A., Xiong, Z., Fadra, T., et al. (2007). Discovery and
optimization of p38 inhibitors via computer-assisted drug design. Journal of Medicinal Chemistry, 50(17), 4016-
4026
 Moss, N., Breitfelder, S., Betageri, R., Cirillo, P. F., Fadra, T., & Hickey, E. R. et al. (2007). New modifications to the
area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP site. Bioorganic
and Medicinal Chemistry Letters, 17(15), 4242-4247
 Hammach, A., Barbosa, A., Gaenzler, F. C., Fadra, T., Goldberg, D., &Hao, M., et al. (2006). Discovery and design of
benzimidazolone based inhibitors of p38 MAP kinase. Bioorganic and Medicinal Chemistry Letters, 16(24), 6316-
6320

3.  Betageri, R., Zhang, Y., Zindell, R. M., Kuzmich, D., Kirrane, T. M., Bentzien, J., &Fadra, T., et al. (2005).
Trifluoromethyl group as a pharmacophore: Effect of replacinga CF 3 group on bindingand agonist activity of a
glucocorticoid receptor ligand. Bioorganic and Medicinal Chemistry Letters, 15(21), 4761-4769